Prelude Therapeutics Inc (PRLD) reported a second-quarter loss that fell short of Wall Street expectations.
The company’s net loss amounted to $34.74 million, or $0.46 per share, compared to a loss of $30.43 million, or $0.54 per share, in the same quarter last year.
Analysts, on average, had projected a loss of $0.43 per share, according to Thomson Reuters data. These estimates typically exclude special items.
Key financial metrics for Prelude Therapeutics Inc (GAAP) for Q2 are as follows:
- Net Loss: $34.74 million, compared to $30.43 million last year.
- Loss Per Share: $0.46, compared to $0.54 last year.
